These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 16570182)

  • 1. The enigmatic nature of apocrine breast lesions.
    Zagorianakou P; Zagorianakou N; Stefanou D; Makrydimas G; Agnantis NJ
    Virchows Arch; 2006 May; 448(5):525-31. PubMed ID: 16570182
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immunohistochemical analysis of apocrine breast lesions. Consistent over-expression of androgen receptor accompanied by the loss of estrogen and progesterone receptors in apocrine metaplasia and apocrine carcinoma in situ.
    Gatalica Z
    Pathol Res Pract; 1997; 193(11-12):753-8. PubMed ID: 9521507
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell turnover in apocrine metaplasia and apocrine adenosis of the breast.
    Elayat G; Selim AG; Wells CA
    Ann Diagn Pathol; 2010 Feb; 14(1):1-7. PubMed ID: 20123450
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The challenge of apocrine proliferations of the breast: a morphologic approach.
    Masood S; Rosa M
    Pathol Res Pract; 2009; 205(3):155-64. PubMed ID: 19147303
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Apocrine epithelium of the breast: does it result from metaplasia?
    Viacava P; Naccarato AG; Bevilacqua G
    Virchows Arch; 1997 Sep; 431(3):205-9. PubMed ID: 9334842
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The spectrum of apocrine lesions of the breast.
    O'Malley FP; Bane AL
    Adv Anat Pathol; 2004 Jan; 11(1):1-9. PubMed ID: 14676636
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diminished number or complete loss of myoepithelial cells associated with metaplastic and neoplastic apocrine lesions of the breast.
    Tramm T; Kim JY; Tavassoli FA
    Am J Surg Pathol; 2011 Feb; 35(2):202-11. PubMed ID: 21263240
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
    Tsutsumi Y
    Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of C-KIT, CD24, CD44s, and COX2 in benign and non-invasive apocrine lesions of the breast.
    Tramm T; Kim JY; Leibl S; Moinfar F; Tavassoli FA
    Virchows Arch; 2016 Sep; 469(3):285-95. PubMed ID: 27287269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of GCDFP-15 and AR decreases in larger or node-positive apocrine carcinomas of the breast.
    Honma N; Takubo K; Akiyama F; Sawabe M; Arai T; Younes M; Kasumi F; Sakamoto G
    Histopathology; 2005 Aug; 47(2):195-201. PubMed ID: 16045781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apocrine lesions of the breast: part 1 of a two-part review: benign, atypical and in situ apocrine proliferations of the breast.
    D'Arcy C; Quinn C
    J Clin Pathol; 2019 Jan; 72(1):1-6. PubMed ID: 30409840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular and diagnostic features of apocrine breast lesions.
    Gromov P; Espinoza JA; Gromova I
    Expert Rev Mol Diagn; 2015; 15(8):1011-22. PubMed ID: 26111757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical Apocrine Adenosis: Diagnostic Challenges and Pitfalls.
    Asirvatham JR; Falcone MM; Kleer CG
    Arch Pathol Lab Med; 2016 Oct; 140(10):1045-51. PubMed ID: 27684975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expression of apocrine differentiation markers in neuroendocrine breast carcinomas of aged women.
    Sapino A; Righi L; Cassoni P; Papotti M; Gugliotta P; Bussolati G
    Mod Pathol; 2001 Aug; 14(8):768-76. PubMed ID: 11504836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cytogenetic comparison of apocrine hyperplasia and apocrine carcinoma of the breast.
    Jones C; Damiani S; Wells D; Chaggar R; Lakhani SR; Eusebi V
    Am J Pathol; 2001 Jan; 158(1):207-14. PubMed ID: 11141494
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The diagnostic utility of EZH2 H-score and Ki-67 index in non-invasive breast apocrine lesions.
    Vougiouklakis T; Belovarac BJ; Lytle A; Chiriboga L; Ozerdem U
    Pathol Res Pract; 2020 Sep; 216(9):153041. PubMed ID: 32825929
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benign and malignant apocrine lesions of the breast.
    Gerhard R; Costa JL; Schmitt F
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):215-21. PubMed ID: 22316369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunohistochemical localisation of androgen receptor in apocrine metaplasia and apocrine adenosis of the breast: relation to oestrogen and progesterone receptors.
    Selim AG; Wells CA
    J Clin Pathol; 1999 Nov; 52(11):838-41. PubMed ID: 10690175
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Histiocytoid change in breast carcinoma: a report of 3 cases with an unusual cytomorphologic pattern of apocrine change.
    Murali R; Salisbury E; Pathmanathan N
    Acta Cytol; 2006; 50(5):548-52. PubMed ID: 17017444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apocrine carcinoma of the breast: a comprehensive review.
    Vranic S; Schmitt F; Sapino A; Costa JL; Reddy S; Castro M; Gatalica Z
    Histol Histopathol; 2013 Nov; 28(11):1393-409. PubMed ID: 23771415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.